Posted by Michael Wonder on 11 Nov 2022
Health Canada approves Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy
10 November 2022 - Camzyos is the only Health Canada approved reversible cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association class II-III in adults.
Today, BMS announced Health Canada's approval of Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association class II-III in adult patients.
